TITLE

PHASE IIB MBI 594AN STUDY VALIDATES ANTI-ACNE PROPERTIES

PUB. DATE
January 2004
SOURCE
Worldwide Biotech;Jan2004, Vol. 16 Issue 1, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
States that Micrologix Biotech Inc., a Vancouver, British Columbia-based developer of anti-infective drugs, has achieved a significant statistics and clinical efficacy results from its Phase Iib study of MBI 594AN topical drug treatment for acne.
ACCESSION #
11805012

 

Related Articles

  • MBI 226 STATISTICAL SUPERIORITY NOT ACHIEVED IN PHASE III.  // Biotech Business;Sep2003, Vol. 16 Issue 9, p8 

    Reports the preliminary results furnished by Micrologix Biotech Inc. and Fujisawa Healthcare Inc. from the MBI 226 Phase III trial demonstrating its statistical superiority in preventing catheter colonization.

  • ACNE BRIEFS.  // Dermatology Times;Mar2003, Vol. 24 Issue 3, p23 

    Reports developments in dermatology as of March 2003. Effect of roaccutane on depression; Percentage of isotretinoin market share gained by Mylan's Amnesteem; Inauguration of the second trial of topical drug MBI 594AN, an alcohol-based solution from Micrologix Biotech Inc.

  • Alternatives to classical curricula: exploring engineer skills of teaching-assistance scholarship holders in not-structured lab lessons of optoelectronic instrumentation. Thé, George André Pereira // International Journal of Electrical Engineering Education;Jul2014, Vol. 51 Issue 3, p174 

    The contribution of teaching-assistant students to the planning and realisation of a new laboratory experiment of an automation engineering course is presented and a number of insights into the benefits of this approach for achieving excellence in undergraduate curricula are discussed in this...

  • Antibacterial agents.  // Formulary;Oct99, Vol. 34 Issue 10, p880 

    Lists the status of the antibacterial agents pending before the United States Food and Drug Administration. Includes status of cefditoren of TAP Holdings and Abbott; Clinafloxacin of Micrologix Biotech and Parke-Davis; Daptomycin of Cubist Pharmaceuticals.

  • PATENTS and Pipelines.  // BioPharm International;Dec2003, Vol. 16 Issue 12, p14 

    This article reports on the development of new drugs. Centocer and Schering-Plough Corp. announced that the European Union has approved maintenance dosing of inflixamab for sustaining clinical response in patients with fistulising Crohn's disease, who have responded to initial inflixamab...

  • Drug testing. Taibbi, Robert // Current Health 2;Mar1993, Vol. 19 Issue 7, p22 

    Presents facts on drug testing. Urine sampling; Drug screening of employees, athletes and former drug addicts undergoing treatment; Blood testing for alcohol; Privacy versus protection.

  • Drugs studied in children.  // FDA Consumer;Mar1991, Vol. 25 Issue 2, p6 

    Lists various drugs that are currently undergoing Food and Drug Administration-sanctioned testing for use in children with AIDS and related disorders.

  • Under the influence of poppy seeds.  // Tufts University Diet & Nutrition Letter;May92, Vol. 10 Issue 3, p2 

    Covers a report by James L. Abelson in the `Journal of the American Medical Association,' in which he states that a women was denied a job because urine samples tested positive for opiates after she had eaten a lemon poppy seed muffin. Effects of opiates; Amount of the drug found in poppy seed...

  • Japan criticised for unsafe drug licenses. Guest, Robert // BMJ: British Medical Journal (International Edition);12/9/95, Vol. 311 Issue 7019, p1521 

    Reports on criticisms against Japan's system for testing and licensing of medicines. Cases of fatal reactions to drugs prescribed with official approval; Comments from Nagoya-based Aichi Cancer Centre doctor Masanori Fukushima; Problems by th ministry of health and welfare.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics